If it does, I might have to sell some of my other stocks and really build a pos. on this one. I love their yearly rev. growth and the upcoming pdufa in Oct. Could be a solid play for the next few years.
Don't bet on it. Another company (Insite vision) has just started a phase II study with a formulation that uses the same drug in Xibrom but with a superior delivery vehicle. They feel so strong about it that one of their study arms is using Xibrom just for the comparison and proving Xibrom inferiority. With Xibrom's lost patent life (Xiday, even if approved would only add 2-3 years more exclusivity and Xiday is in fact just Xibrom so no innovations there),..ISTA needs to pull a lot of rabbit outta hat to compensate for the upcoming revenue loss.